The Roivant subsidiary Kinevant is to discontinue further development of namilumab for the treatment of sarcoidosis.

Tyr Pharma, Inc. (NASDAQ:ATYR), a clinical-stage biotechnology company valued at $286.24 million, is garnering attention from investors and analysts alike as it advances its lead candidate, ...

(RTTNews) - aTyr Pharma, Inc. (ATYR), a clinical-stage biotechnology company, on Wednesday announced that it will present three important posters on efzofitimod at the American Thoracic Society or ...

The posters will cover the largest placebo-controlled trial in pulmonary sarcoidosis, real-world treatment patterns, and the incidence and mortality of the disease in the U.S. Efzofitimod ...

More than 2,500 patients are currently waiting for that lifesaving transplant in Michigan. More than 100,000 are waiting ...

The firm has strong confidence aTyr’s lead program efzofitimod will be successful in its ongoing Phase 3 study in pulmonary sarcoidosis, with topline results expected in Q3 2025. The Phase 3 EFZO-FIT ...

Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized by the formation of noncaseating granulomas, multisystem involvement, intrathoracic (pulmonary and lymph node ...

Leerink analyst Faisal A. Khurshid initiated coverage of aTyr Pharma (ATYR) with an Outperform rating and $16 price target The firm has strong ...

Children diagnosed with interstitial lung disease often survive into adulthood, when they are likely to need care for related impairments.

However, pulmonary manifestations and symmetric oligoarthritis ... the most likely autoimmune disorder in this case is sarcoidosis. This multisystem granulomatous disorder can involve any organ ...